PGRN-RIKEN-CALGB 80303 - Genome-wide Pharmacogenomic Study of Gemcitabine and Bevacizumab in Advanced Pancreatic Cancer. Homo sapiens
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA75655
下载链接
链接失效反馈官方服务：
资源简介：
CALGB 80303 was a randomized, phase III study in advanced pancreatic cancer patients treated with Gemcitabine plus either Bevacizumab or placebo. No difference in overall survival (OS) was observed between the two arms. We prospectively collected germline DNA and conducted a genome-wide association study (GWAS).
创建时间：
2011-07-20
